HOME >> MEDICINE >> NEWS
New protease inhibitor held HIV at undetectable levels for four years

A study from The Feinberg School of Medicine has shown that the protease inhibitor lopinavir/ritonavir (Kaletra) suppressed HIV to undetectable levels and was well tolerated through four years of treatment in patients who had not previously received antiretroviral therapy.

To date in the Kaletra study, none of the patients has developed resistance to Kaletra or other protease inhibitors. Kaletra is thus far the only protease inhibitor for which resistance has not been observed in patients receiving it as an initial therapy.

Robert L. Murphy, M.D., professor of medicine at the Feinberg School and director of HIV/AIDS clinical research at Northwestern University, presented results of the study today at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy.

"Maintaining antiviral suppression to undetectable levels over the long term is crucial to patients' success," Murphy said.

"Drugs such as Kaletra, which have demonstrated high rates of viral suppression over several years, remain important options for initial therapy. Viral suppression helps prolong the time to development of resistance, which is an important cause of treatment failure," Murphy said.

In this ongoing phase II study, 100 patients who had not previously received antiretroviral therapy were given one of three doses of Kaletra in addition to the nucleoside analogues stavudine and lamivudine.

After 48 weeks, therapy for all patients was converted to the same dose of Kaletra with stavudine and lamivudine. Of the original group of patients, 72 remained in the study through four years; seven of the 28 patients who discontinued therapy did so because of adverse events attributed to Kaletra. All 72 patients maintained an undetectable HIV viral load of less than 400 copies per milliliter, and their CD4 counts increased consistently from the beginning of the study over the four-year period (mean increase of 416 cells per cubic millimeter).

Ka
'"/>

Contact: Elizabeth Crown
e-crown@northwestern.edu
312-503-8928
Northwestern University
27-Sep-2002


Page: 1 2

Related medicine news :

1. HIV patients may be at risk of heart problems when taking protease inhibitor drugs
2. HIV-1 protease inhibitors: Effective against malaria?
3. FDA approves new HIV protease inhibitor, Lexiva (TM)
4. Pharmacokinetic data presented at ICAAC on investigational HIV protease inhibitor 433908 (908)
5. Molecules inhibit HIV protease, could lead to new line of attack against AIDS
6. Study compares efficacy and adherence to triple nucleoside therapy Ziagen + Combivir with protease inhibitor plus Combivir regimens in therapy-nave
7. Two studies compare triple nucleoside therapy Ziagen® + Combivir® with protease inhibitorplus Combivir® regimens in therapy-naive patients
8. COX-2 inhibitors associated with blood pressure elevation
9. COX-2 inhibitor increases the risk of heart attack in elderly adults with no history of heart attack
10. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
11. Penn researchers add more evidence to demonstrate role of COX inhibitors in heart-disease risk

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/13/2018)... ... September 13, 2018 , ... Nash Family ... Month to educate their patients and the general public on the value of ... Not only do Drs. Nash have extensive training in helping those with periodontal ...
(Date:9/13/2018)... ... 2018 , ... Pulsara is honored to be represented by its CEO, Dr. ... 19-22 in Chicago. Dr. Woodson, ER Physician and Founder/CEO of Pulsara, has been ... Clinical Communication & Collaboration (CC&C) is Not Enough: Why You Need a Regional Communication ...
(Date:9/12/2018)... (PRWEB) , ... September 12, 2018 , ... Today, ... Ewing and Maureen Beck, attempted the first unassisted adaptive climb of the Lotus Flower ... illness, which made it difficult for him to lead, the duo decided to persevere ...
(Date:9/12/2018)... (PRWEB) , ... September 13, 2018 , ... Donaldson Plastic ... companies, as well as Columbus Business First's Fast 50 list of central Ohio's fastest ... with a 3-year growth rate of 81 percent. It is the only medical practice ...
(Date:9/7/2018)... ... September 07, 2018 , ... ... products with a presence worldwide, today announced that its Chief Executive Officer, Asma ... Entrepreneurship. Ms. Ishaq will be presented the award on Friday, September 7, at ...
Breaking Medicine News(10 mins):
(Date:9/12/2018)... ... September 12, 2018 , ... ... Cycle Conference in Chicago, IL, from September 19-22. The IT + Revenue Cycle ... patient engagement and empowerment with the use of Precision Virtual Reality™ medical visualization ...
(Date:9/7/2018)... FOLSOM, Calif. (PRWEB) , ... September 06, 2018 , ... ... Best Overall Scientific Paper Award for his presentation of: IDEAL IMPLANT® - Seven-Year Clinical ... asked to present the paper again at the upcoming ASPS (American Society of Plastic ...
(Date:9/1/2018)... (PRWEB) , ... August 31, 2018 , ... ... Committee have launched the College’s search for a Vice President/ Dean of Academic ... Dean of Academic Affairs (VP/Dean AA) is the chief academic officer responsible for ...
Breaking Medicine Technology:
Cached News: